Stephanie and Tristan

LIVING WITH SICKLE CELL DISEASE

Corporate

Effectiveness

Addressing ESG & Long-term

Sustainability

April 2024

© 2024 Editas Medicine 1

Forward Looking Statements

This presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ''anticipate,'' ''believe,'' ''continue,'' ''could,'' ''estimate,'' ''expect,'' ''intend,'' ''may,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''target,'' ''should,'' ''would,'' and similar expressions are intended

to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials, including the RUBY and EdiTHAL trials, and clinical development of the Company's product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company's subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this presentation represent Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

All information in this presentation isprovided as of April 15, 2024, unless otherwise specified.

2

© 2024 Editas Medicine

A MESSAGE FROM

Gilmore O'Neill

PRESIDENT & CEO

In 2023, Editas Medicine celebrated its 10th Anniversary as the Company formed just after the discovery of the CRISPR gene editing technology. As we reflect on our 10 years as a Company, we are not just convinced about the potential of gene editing to make a positive difference in the world, we are seeing evidence of that potential in the clinic and in our discovery efforts in the lab.

I joined Editas almost two years ago to lead the Company as we use this extraordinary technology to create potentially life-changing medicines developed to treat diseases previously thought untreatable. During these two years, we have accomplished many important achievements, and we have proved our resilience as a Company and as a community as we work in a new normal following the many challenges of the past few years including economic instability and increased attacks on marginalized groups. All of these challenges have impacted our patients, our families and friends, and our broader communities, and I am proud of our employees and their dedication to our mission to develop novel, transformative gene editing medicines for people living with serious diseases.

I believe the lessons learned from these challenges and our society's ongoing struggle to overcome them will continue to impact the increasing expectations of corporate responsibility. At Editas, we are committed to doing our part to address them as effective corporate stewards.

As a physician by training, I am very pleased with the connections our employees build with people who suffer from the diseases Editas seeks to treat. Sickle cell disease is a devastating disease, and even more devastating are the heartbreaking stories patients have shared with us about how they live their daily lives in fear of their disease while also being marginalized and mistreated because of their disease and their ethnicity, thus diminishing their access to equitable healthcare and other health disparities. We recognize that people of color experience many diseases at higher rates than the general population, while having less access to healthcare and suffering poorer health outcomes. As Editas continues to evolve and expand, our bandwidth to address these health disparities and our relationships with these patients grows as well.

Every day at Editas, our goal remains to develop treatments to give people living with serious diseases a better quality of life and possibly even a functional cure for their disease. Our diverse leadership team and board remain committed to delivering new, innovative medicines to patients while facilitating a safe, inclusive, and collaborative culture that is committed to our communities and respectful of our environment. Our governance structure and diverse workforce champion sustainability and long-term thinking. Our responsibilities and values are embedded in our everyday principles as we strive to reach our highest potential for all our stakeholders. We look forward to updating you on our continued progress in achieving this objective.

…our goal remains to

develop treatments to give people living with serious diseases a better quality of life and possibly even a functional cure for their

disease."

© 2024 Editas Medicine 3

Editas Medicine is a Leader in the CRISPR-based Gene Editing Medicine Field

  • Our lead product candidate, reni-cel, is an investigational gene editing medicine that is a potential
    "best in class" treatment for sickle cell disease and beta thalassemia
  • Ongoing RUBY and EdiTHAL clinical trials
  • Editas holds an exclusive license to foundational IP for Cas9 and Cas12a for the prevention or treatment of human disease from the Broad Institute and Harvard University
  • Source of non-dilutive capital
  1. Granted Cas9 sublicenses, including non-exclusive licenses to Vertex Pharmaceuticals and Vor Bio
  • Proprietary AsCas12a is a high fidelity and high efficiency CRISPR nuclease
  • Core expertise in guide RNA design and chemistry for high precision editing
  • Longer-termfocus on creating important medicines based on in vivo gene editing
  • Scaled Chemistry, Manufacturing, and Controls (CMC)
  • Leadership team with a proven track record of drug development and commercialization

4

© 2024 Editas Medicine

Leading in an Interconnected Gene Editing World

OBJECTIVES

  1. Shaping the broader field of genome editing
  2. Ensuring patient access to our prospective CRISPR-based medicines
  3. Driving corporate stewardship as a genomic medicine leader

KEY STAKEHOLDERS

  • Patients & caregivers
  • Patient groups
  • Investors & analysts
  • Regulators
  • Policy leaders
  • NGO's
  • Payors
  • Scientists & KOLs
  • Bioethicists
  • Influencers

5

© 2024 Editas Medicine

Our Commitment to Patients

ENGAGE REGULARLY Seek out opportunities to learn from the communities we aim to create a treatment option for and continue to bring their voices into decision making and drug development planning.

LISTEN ACTIVELY Health and treatment is deeply personal, and there are similarities and differences across diseases, and among individuals affected by the same disease. It is critical that we listen and understand diverse perspectives.

ENGAGE AUTHENTICALLY We are optimistic about the promise of gene editing, yet there is still much to be learned. Through transparent communication about Editas Medicine and our approach to developing medicines, we hope to ensure the expectations we set are realistic.

In 2022, Editas established two advisory councils- one for sickle cell disease and one for transfusion- dependent beta thalassemia - comprised of patients and caregivers who guide and advise Editas throughout the drug development cycle.

STEPHANIE

Living with sickle cell disease

For us, the patient and caregiver is - and must be - at the center of everything we do. We are acutely aware that gene editing represents a transformative technology that evokes both excitement and curiosity. We believe it is critical to be transparent about our science and engage responsibly with the patient and caregiver communities we seek to help.

© 2024 Editas Medicine 6

Community Engagement

Editas is proud to be a founding member of the Sickle Cell Disease Partnership, a multi-sector alliance of patient advocates, healthcare providers, and biopharmaceutical industry leaders to advocate for policies that improve quality and access to care for the sickle cell community.

As a Corporate Advisory Counsel member and sponsor of the Sick Cells ambassador program since 2022, Editas supports a volunteer network of sickle cell advocates dedicated to changing the landscape of sickle cell disease. The program aims to educate policymakers, connect the sickle cell community, and activate advocates to spread awareness to the broader community.

The Sickle Cell Reproductive Health Education Directive (SC RED) advocates for high quality sexual and reproductive health care for individuals living with all types of sickle cell disease. Editas is proud to sponsor a number of educational initiatives since 2022.

Editas has attended Cooley's Anemia Foundation's Patient-Family Conference since 2022 to connect with and learn from the thalassemia community. Members of the thalassemia community participated in a workshop to name our TDT clinical trial, EdiThal!

Editas is a founding member of the sickle cell C.A.R.E.S. Consortium, an initiative of the Sickle Cell Disease Association of America (SCDAA) to raise awareness about the importance of clinical trial participation and education, and therefore better options for the treatment of sickle cell disease.

The Consortium is comprised of sickle cell community-based organizations (CBOs), patient and caregiver advocates, community partners and medical and research advisers. The Consortium defines problems and gaps in the SCD community, identifies strategies to address those needs and gaps, and determine the CBO, Community, and Corporate partnerships best equipped to implement those strategies to achieve significant and sustainable change.

Cayenne Wellness Center and Children's Foundation addresses the

urgent needs of adults with SCD and their community of caregivers,

TRISTAN

Living with sickle cell disease

Editas is honored to support and learn from community partners to raise awareness and understanding of the serious diseases we aim to create treatments for. Together, we work to meet unmet needs and improve the lives of patients.

healthcare providers, and social support organizations. Editas supports a

number of initiatives from Cayenne Wellness including educational

© 2024 Editas Medicine

7

programming for SCD therapies and mental health.

Executive Compensation Philosophy

Our goal is to implement an executive compensation program that attracts and retains qualified and talented executives, motivates such executives to achieve our business goals and rewards them for short-and long-term performance with a simple and clear compensation structure.

Maintain and evaluate annually an industry-specific peer group for benchmarking pay

• Review annually our compensation strategy to ensure target

pay is based on market norms

  • No employment agreements that guarantee a certain compensation level or employment term
    • No guaranteedannual salary increases or guaranteed bonuses

• Balance short- and long-term incentives

(through annual cash bonuses and equity awards)WE

• Maintain a compensation recovery or "clawback" policy

DO

•

Set robust executive and non-employee director

Stock Ownership Guidelines

•

Use multiple performance measures to

determine incentive payouts, include caps on annual

incentive payments

WE

DON'T

    • No single-trigger vesting in connection with a change-in-control for equity awards
      • No excessive executive perquisites or personal benefits
      • No hedging or pledging orspeculative transaction in our securities
  • No re-pricing of equity awards without stockholder approval

• Engage an independent compensation consultant

  • No excise tax gross-ups

8

© 2024 Editas Medicine

Performance Based Executive Compensation Model

2023 Target

Executive Compensation1

Incentives linked to actions that create sustainable stockholder value

Significant equity focus strengthens alignment of interests with those of long-term stockholders

Significant majority of pay is at-risk

No guaranteed bonus or awards

No guaranteed employment term

1 Charts reflect target 2023 pay mix (excluding benefits) for Gilmore O'Neill, our chief executive officer, and for our other named executive officers ("NEOs"). Please see our proxy statement for the

2024 annual meeting of stockholders, available from the Securities and Exchange Commission, for additional information.

9

© 2024 Editas Medicine

Diverse and Experienced Board of Directors

Emma Reeve

Meeta Chatterjee, Ph.D.

Independent director since 2021, Chair since June 2023

Independent director since 2020

Former CFO,

Chief Strategy Officer,

Constellation Pharmaceuticals

Sun Pharmaceutical Industries, Inc.

Andrew Hirsch

Jessica Hopfield, Ph.D.

Independent director since 2017

Independent director since 2018

Principal,

President & CEO,

J. Hopfield Consulting

C4 Therapeutics

Gilmore O'Neill, M.B., M.M.Sc.

David Scadden, M.D.

Independent director since 2019

President and CEO,

Gerald & Darlene Jordan Professor of Medicine

Editas Medicine

Harvard University

Bernadette Connaughton

Independent director since 2021

Former President, Intercontinental,

Bristol Myers Squibb

Elliott Levy, M.D.

Independent director since April 2023

Venture Partner,

5AM Venture Management, LLC

Akshay Vaishnaw, M.D., Ph.D.

Independent director since 2016

Chief Innovation Officer, Alnylam Pharmaceuticals;

10

Venture Partner, Atlas Ventures

© 2024 Editas Medicine

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Editas Medicine Inc. published this content on 12 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 April 2024 21:52:35 UTC.